Adjuvant aromatase inhibitor therapy and early markers for cardiovascular disease in breast cancer survivors

被引:0
|
作者
Annemiek van Ommen-Nijhof
Judy N. Jacobse
Lars C. Steggink
Joop D. Lefrandt
Jourik A. Gietema
Flora E. van Leeuwen
Michael Schaapveld
Gabe S. Sonke
机构
[1] The Netherlands Cancer Institute,Department of Medical Oncology
[2] Leiden University Medical Center,Department of Radiotherapy
[3] Erasmus University Medical Center,Department of Medical Oncology
[4] University Medical Center Groningen,Department of Internal Medicine
[5] University Medical Center Groningen,Department of Medical Oncology
[6] The Netherlands Cancer Institute,Department of Psychosocial Research and Epidemiology
[7] The Netherlands Cancer Institute,Department of Medical Oncology
[8] University of Amsterdam,Department of Medical Oncology
来源
Breast Cancer Research and Treatment | 2022年 / 196卷
关键词
Breast cancer; Endocrine therapy; Aromatase inhibitor; Cardiovascular disease;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:591 / 602
页数:11
相关论文
共 50 条
  • [31] Aromatase inhibitor plus ovarian suppression as adjuvant therapy in premenopausal women with breast cancer
    Figg, William D., II
    Cook, Katherine
    Clarke, Robert
    CANCER BIOLOGY & THERAPY, 2014, 15 (12) : 1586 - 1587
  • [32] Duration of aromatase inhibitor use and long-term cardiovascular risk in breast cancer survivors
    Huang, Yuhan
    Kwan, Marilyn L.
    Heckbert, Susan R.
    Smith, Nicholas L.
    Othus, Megan
    Laurent, Cecile A.
    Roh, Janise M.
    Rillamas-Sun, Eileen
    Lee, Valerie S.
    Kolevska, Tatjana
    Cheng, Richard K.
    Irribarren, Carlos
    Nguyen-Huynh, Mai
    Hershman, Dawn L.
    Kushi, Lawrence H.
    Greenlee, Heather
    JNCI CANCER SPECTRUM, 2025, 9 (01)
  • [33] Sleep disturbances and restless legs syndrome in postmenopausal women with early breast cancer given adjuvant aromatase inhibitor therapy
    Pedersini, Rebecca
    di Mauro, Pierluigi
    Amoroso, Vito
    Castronovo, Vincenza
    Zamparini, Manuel
    Monteverdi, Sara
    Laini, Lara
    Schivardi, Greta
    Cosentini, Deborah
    Grisanti, Salvatore
    Marelli, Sara
    Strambi, Luigi Ferini
    Berruti, Alfredo
    BREAST, 2022, 66 : 162 - 168
  • [34] Safety of aromatase inhibitor therapy in breast cancer
    Lintermans, Anneleen
    Neven, Patrick
    EXPERT OPINION ON DRUG SAFETY, 2015, 14 (08) : 1201 - 1211
  • [35] Sexual Dysfunction and Aromatase Inhibitor Use in Survivors of Breast Cancer
    Kwan, Karen W.
    Chlebowski, Rowan T.
    CLINICAL BREAST CANCER, 2009, 9 (04) : 219 - 224
  • [36] Bisphosphonate therapy requirement during adjuvant aromatase inhibitor therapy in early breast cancer patients according to UK bone health guidelines
    Moe, M.
    Almatari, M.
    Ali, P.
    Willshaw, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [37] Effect of Aromatase Inhibitor Therapy on the Cardiovascular Health of Black and White Breast Cancer Patients
    Gallicchio, Lisa
    Calhoun, Carla
    Helzlsouer, Kathy
    CLINICAL BREAST CANCER, 2016, 16 (03) : E23 - E31
  • [38] Study of Neurobehavioral Symptoms and Impairments in Breast Cancer Patients Receiving Adjuvant Aromatase Inhibitor Therapy
    Weaver, J. R.
    Stark, S. M.
    Shahverdi, K. T.
    Jeter, S.
    Zorzi, J.
    Skolasky, Jr R. L.
    Andrejczuk, M. A.
    Stearns, V
    Gordon, B.
    CANCER RESEARCH, 2009, 69 (24) : 734S - 734S
  • [39] Joint pain and physical activity among breast cancer survivors on aromatase inhibitor therapy.
    Nyrop, Kirsten A.
    Muss, Hyman
    Hackney, Betsy
    Clevalend, Rebecca
    Callahan, Leigh F.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [40] Adherence to Adjuvant Aromatase Inhibitor Therapy Among Postmenopausal Hispanic/Latino Women With Breast Cancer
    Philipovskiy, Alexander
    Campbell, Aleli
    Heydarian, Rosalinda
    Castillo, Brenda
    Dwivedi, Alok K.
    Mccallum, Richard
    Aguilera, Renato
    Gaur, Sumit
    Nahleh, Zeina
    ANTICANCER RESEARCH, 2020, 40 (02) : 857 - 864